Pidilizumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Pidilizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target PD-1
Identifiers
CAS Number 1036730-42-3
ATC code none
Chemical data
Formula C6424H9920N1704O2002S48
Molecular mass 147.43 kg/mol

Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.[1][2] Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, but this is currently uncertain.[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.

Clinical trials

It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.[4] A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. An add-on trial for multiple myeloma is ongoing.[5]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.
  3. ↑ http://www.fiercebiotech.com/story/anti-pd-1-well-no-says-medivation-partial-hold-forces-halt-pivotal-cancer-s/2016-01-26
  4. ↑ Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data. Sept 2011
  5. ↑ Lua error in package.lua at line 80: module 'strict' not found.


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Pidilizumab&oldid=708439842"